

BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS



BIO061C
April 2014

Jackson Highsmith
Project Analyst

ISBN: 1-56965-801-3



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	3
METHODOLOGY AND INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE GLOBAL BIOMARKERS FORECAST BY SEGMENT, THROUGH 2018 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL BIOMARKERS FORECAST BY SEGMENT, 2011-2018 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW	11
INTRODUCTION	11
<i>TABLE 1 GLOBAL MARKET FOR BIOMARKERS, THROUGH 2013 (\$ MILLIONS)</i>	12
ENABLING ADVANCEMENTS DRIVING MARKET GROWTH	12
BIOMARKERS DRIVE SPEED, COST AND QUALITY IMPROVEMENTS ACROSS THE DRUG DEVELOPMENT SPECTRUM	12
COST REDUCTION OPPORTUNITIES ARISING FROM BIOMARKER APPLICATIONS	13
Elements of Cost in Healthcare	14
STRATEGIC BIOMARKER APPLICATIONS	15
Targeted Therapies	15
Product Extensions	16
Ultra-Blockbuster	17
BIOMARKER APPLICATIONS: DRUG DEVELOPMENT	17
Safety/Toxicology Biomarkers	18
<i>TABLE 2 NOVEL SAFETY/TOXICOLOGY BIOMARKERS USED IN CANCER, CARDIO AND RENAL</i>	19
Dose Selection and Dose Optimization	19
<i>TABLE 3 NOVEL DOSE SELECTION BIOMARKERS USED IN CANCER, DIABETES, METABOLIC AND LIVER DISEASE</i>	20
Improved Measurement of Therapeutic Efficacy	20
Outcome Biomarkers and Surrogate Endpoints	21
<i>TABLE 4 PATIENT OUTCOME MEASUREMENTS BIOMARKERS</i>	21
EARLY-STAGE CLINICAL TRIAL APPLICATIONS	21
LATE-STAGE CLINICAL TRIAL APPLICATIONS	22
Phase III	22
Phase IV	22
BIOMARKERS: CHALLENGES AND OPPORTUNITIES	22
SUMMARY	22
CHALLENGES	24

TOPIC	PAGE NO.
OPPORTUNITIES	25
CLINICAL VALIDITY: REQUIREMENTS	26
BIOMARKER OPPORTUNITIES	26
PRODUCT SUMMARY AND MARKET	26
GENOMICS	26
<i>TABLE 5 GLOBAL MARKET FOR BIOMARKERS, 2013 (\$ MILLIONS)</i>	27
IMAGING	27
PROTEOMICS	27
BIOINFORMATICS	28
OTHER	29
Metabolomics	29
BIOMARKER ADOPTION BY THE PHARMACEUTICAL INDUSTRY	29
GROWTH DRIVERS AND RESISTORS	29
FACTORS INFLUENCING BIOMARKER ADOPTION IN CLINICAL TRIALS	29
CLINICAL TRIAL BENEFITS: COST AND RISK AVOIDANCE	30
IMPACT OF DRUG FAILURE IN LATE-STAGE CLINICAL TRIALS	30
Merck: Vicriviroc	30
Myriad: Flurizan	31
ADDITIONAL CAPABILITIES BY LARGE SERVICE PLAYERS	31
TECHNOLOGICAL ADVANCEMENTS IN GENOMICS AND PROTEOMICS	31
BIOMARKER MARKET FORECAST	31
<i>TABLE 6 GLOBAL BIOMARKER MARKET FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	32
CHAPTER 4 REGULATORY DYNAMICS, INTELLECTUAL PROPERTY AND ETHICAL CONSIDERATIONS	34
INTRODUCTION	34
BIOMARKER LABORATORY REGULATORY SUMMARY	34
DEFINITION OF AN IVD COMPANION DIAGNOSTIC	35
Labeling	37
Investigational Use	38
MINI REVIEW OF FDA GUIDANCE ON APPROVAL OF THE COMPANION DIAGNOSTIC	38
Summary	38
Timing Considerations	39
Regulatory Pathways Outside of the United States	39
510(k) vs PMA	40
ASSAY DEVELOPMENT AND VALIDATION IN DRUG DIAGNOSTIC CO-DEVELOPMENT	41
Overview	41
General Considerations in Drug Diagnostic Co-Development	42
Implementation of Companion Diagnostic in Clinical Design	42
Two-Arm Clinical Design	43
Randomization with the Diagnostic	43
Restricted Approach	44
Establishing a Training and Test Set of Samples	45
Patient Population Consistency	45
Iterative Evaluation Cycles	46
Clinical Material Considerations	46

TOPIC	PAGE NO.
Technical Considerations	47
Testing Volume	47
Ease of Use	48
Number of Analytes	48
Multiple Analyte versus Few Analyte Classifiers	49
Instrument	50
Reagent Status	51
Assay Validation	51
Assay Characterization or Qualification	51
Analytical Validation of a Companion Diagnostic	52
Studies to Demonstrate Accuracy, Precision, Specificity and Sensitivity	53
Sample Requirements	54
Analyte Concentration Specifications	54
Cutoff Establishment	54
Controls and Calibrators	55
Precision	56
Analytical Specificity	56
Assay Conditions	57
Sample Carryover	57
Limiting Factors	57
CLINICAL VALIDATION	57
ROLE OF THE FOOD AND DRUG ADMINISTRATION	58
<i>TABLE 7 FDA GUIDELINES FOR BIOMARKER APPLICATIONS</i>	59
EUROPEAN MEDICINES AGENCY	60
REGULATORY IMPACT ON DRUG SAFETY	60
INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING	61
APPROVED PATENT ANALYSIS	61
<i>TABLE 8 ANNUAL PATENTS FILED AND APPROVED WITH BIOMARKER CLAIMS IN THE U.S., EUROPE AND JAPAN, THROUGH 2013</i>	61
COMPETITIVE LANDSCAPE	61
LATE-STAGE CLINICAL TRIALS: COMPETITIVE POSITIONING	62
<i>TABLE 9 CURRENT GLOBAL MARKET FOR TOTAL CLINICAL STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH 2018 (\$ MILLIONS)</i>	62
<i>TABLE 10 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER DELIVERY, 2007-2013</i>	63
<i>TABLE 11 REPRESENTATIVE LIST OF INDUSTRY ADVANCEMENTS AND APPROVED BIOMARKER PATENTS IN THE U.S., EUROPE AND JAPAN</i>	66
ETHICAL CONSIDERATIONS	69
SUMMARY	69
Respect for Persons	71
Beneficence	71
Justice	72
BIOMARKER APPLICATIONS OF ETHICAL CONSIDERATIONS	72
Race and Genotype	72
Negligence	72
Informed Consent	73
Privacy	73

TOPIC	PAGE NO.
Market Segmentation	74
Professional, Media and Opinion Leader Edification	74
REGULATORY IMPLICATIONS	75
CHAPTER 5 APPLICATION BY THERAPY AREA	77
<i>TABLE 12 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS BY THERAPEUTIC AREA, THROUGH 2018 (\$ MILLIONS)</i>	80
ONCOLOGY	80
<i>TABLE 13 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: ONCOLOGY</i>	81
BREAST CANCER	81
MAMMAPRINT	82
<i>TABLE 14 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: BREAST CANCER</i>	83
ONCOTYPE DX	83
TEST ADOPTION	84
COLORECTAL CANCER	86
CETUXIMAB	86
PANITUMUMAB	88
ELESCLOMOL	90
HERCEPTIN	90
OTHER PREDICTIVE TESTS	90
<i>TABLE 15 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: ONCOLOGY, 2005-2009</i>	91
OTHER PROGNOSTIC TESTS	92
PREDICTIVE TESTS IN BREAST CANCER	94
HORMONAL THERAPIES	94
TAXANES/ANTHRACYCLINES	96
BIOLOGICALS	98
TRIPLE NEGATIVE BREAST CANCER	99
OTHER NOVEL BIOMARKERS	100
LUNG CANCER	101
INTRODUCTION	101
PREDICTIVE TESTS	102
<i>TABLE 16 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: LUNG CANCER</i>	102
GEFITINIB	103
ERLOTINIB	104
OTHER PREDICTIVE TESTS	106
NOVEL THERAPIES	106
OTHER ONCOLOGY	107
PROSTATE CANCER	107
OVARIAN CANCER	109
MALIGNANT MELANOMA	109
<i>TABLE 17 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: MALIGNANT MELANOMA</i>	110
OTHER DISEASES	111
CARDIOVASCULAR	111
<i>TABLE 18 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: CARDIOVASCULAR</i>	111

TOPIC	PAGE NO.
<i>TABLE 19 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR</i>	113
CENTRAL NERVOUS SYSTEM	113
<i>TABLE 20 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE</i>	115
IMMUNOLOGY	115
<i>TABLE 21 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY</i>	116
Immunology: Benlysta: Human Genome Sciences	116
EXPEDITION and IDENTITY Alzheimer's Trial: Eli Lilly	117
CLINICAL BIOMARKERS: THERAPEUTIC DISEASE MARKET FORECAST	117
<i>TABLE 22 GLOBAL MARKET FORECAST FOR CLINICAL STAGE BIOMARKERS, THROUGH 2018 (\$ MILLIONS)</i>	117
<i>TABLE 23 GLOBAL MARKET FORECAST OF BIOMARKERS IN LATE-STAGE CLINICAL USE BY THERAPEUTIC AREA, THROUGH 2018 (\$ MILLIONS)</i>	117
CHAPTER 6 BIOMARKERS ACTIVELY GUIDING DRUG DEVELOPMENT	119
INTRODUCTION	119
<i>TABLE 24 RECENT CORPORATE ALLIANCES BETWEEN BIOMARKER AND DRUG DEVELOPMENT COMPANIES</i>	120
ASURAGEN	120
BACKGROUND	120
COLLABORATION: MERCK & CO.	121
BG MEDICINE	121
BACKGROUND	121
COLLABORATION: CORDEX PHARMA	121
COLLABORATION: SIEMENS	121
BIOMERIEUX	122
BACKGROUND	122
COLLABORATIONS: ISPEN	122
ADNA PROJECT	122
CELERA	124
BACKGROUND	124
COLLABORATIONS	124
Abbott	124
Merck & Co.	124
Ipsen	124
AVACTA	125
BACKGROUND	125
COLLABORATION: TAKEDA	125
DAKO	125
BACKGROUND	125
COLLABORATIONS	125
Genentech	125
Bristol-Myers Squibb	126
DXS	126
BACKGROUND	126
COLLABORATIONS	127
Amgen	127
Roche Molecular Diagnostics	127
GE HEALTHCARE	128

TOPIC	PAGE NO.
BACKGROUND	128
COLLABORATION: ELI LILLY	128
GENOMIC HEALTH	128
BACKGROUND	128
COLLABORATIONS	128
Pfizer	128
Bristol-Myers Squibb and ImClone Systems	129
HISTORX	129
BACKGROUND	129
COLLABORATION	129
Lilly	129
LABCORP	130
BACKGROUND	130
COLLABORATIONS	130
ARCA biopharma	130
Vanda Pharmaceuticals	131
Medco Health Solutions	132
MONOGRAM BIOSCIENCES (A LABCORP COMPANY)	132
BACKGROUND	132
COLLABORATIONS	132
Pfizer HIV partnership	132
VeraTag Oncology Platform	132
ONCOMETHYLOME SCIENCES (NOW MDX HEALTH)	133
BACKGROUND	133
COLLABORATIONS	133
Merck KGaA	133
Schering-Plough	133
GlaxoSmithKline Biologicals	133
Abbott	134
XDX	134
BACKGROUND	134
COLLABORATION	134
Bristol-Myers Squibb	134
CHAPTER 7 COMPANY ANALYSIS	136
<i>TABLE 25 PRINCIPAL FOCUS OF BIOMARKERS: PHARMACEUTICAL COMPANIES BY THERAPEUTIC AREA</i>	136
ABBOTT LABORATORIES INC.	136
COMPANY OVERVIEW	136
PRODUCTS AND SERVICES	136
<i>TABLE 26 ABBOTT: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	137
COMPANY STRATEGY	137
AFFYMETRIX INC.	138
COMPANY OVERVIEW	138
PRODUCTS AND SERVICES	138
<i>TABLE 27 AFFYMETRIX: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	138

TOPIC	PAGE NO.
COMPANY STRATEGY	138
ASTELLAS PHARMA INC.	139
COMPANY OVERVIEW	139
PRODUCTS AND SERVICES	139
<i>TABLE 28 ASTELLAS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	140
COMPANY STRATEGY	140
ASTRAZENECA LTD.	140
COMPANY OVERVIEW	141
PRODUCTS AND SERVICES	141
<i>TABLE 29 ASTRAZENECA: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	141
COMPANY STRATEGY	142
BANYAN BIOMARKERS INC.	142
COMPANY OVERVIEW	142
PRODUCTS AND SERVICES	142
<i>TABLE 30 BANYAN: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	142
COMPANY STRATEGY	143
BAYER SCHERING PHARMA AG	143
COMPANY OVERVIEW	143
PRODUCTS AND SERVICES	143
<i>TABLE 31 BAYER SCHERING: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	144
COMPANY STRATEGY	144
BG MEDICINE INC.	146
COMPANY OVERVIEW	146
PRODUCTS AND SERVICES	146
<i>TABLE 32 BIOPHYSICAL: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	146
COMPANY STRATEGY	146
BIOPHYSICAL CORP.	147
COMPANY OVERVIEW	147
PRODUCTS AND SERVICES	147
<i>TABLE 33 BIOSYSTEMS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	148
COMPANY STRATEGY	148
BIOSYSTEMS INTERNATIONAL INC.	148
COMPANY OVERVIEW	148
PRODUCTS AND SERVICES	149
COMPANY STRATEGY	149
BOEHRINGER INGELHEIM GMBH	149
COMPANY OVERVIEW	149
PRODUCTS AND SERVICES	149
<i>TABLE 34 BMS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	150
COMPANY STRATEGY	150
BRISTOL-MYERS SQUIBB CO.	150
COMPANY OVERVIEW	151

TOPIC	PAGE NO.
PRODUCTS AND SERVICES	151
<i>TABLE 35 BMS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	151
COMPANY STRATEGY	151
CAPRION PROTEOMICS INC.	152
COMPANY OVERVIEW	152
PRODUCTS AND SERVICES	152
COMPANY STRATEGY	153
Infectious Diseases	153
Diabetes and Metabolic Disease	153
Oncology	153
DAIICHI SANKYO CO. LTD.	154
COMPANY OVERVIEW	154
PRODUCTS AND SERVICES	154
<i>TABLE 36 DAIICHI SANKYO: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	155
COMPANY STRATEGY	155
EISAI CO. LTD.	155
COMPANY OVERVIEW	156
PRODUCTS AND SERVICES	156
<i>TABLE 37 EISAI: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	156
COMPANY STRATEGY	156
ELI LILLY AND CO.	157
COMPANY OVERVIEW	157
PRODUCTS AND SERVICES	157
<i>TABLE 38 ELI LILLY: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	157
COMPANY STRATEGY	158
EPIGENOMICS AG	158
COMPANY OVERVIEW	158
PRODUCTS AND SERVICES	159
<i>TABLE 39 EPIGENOMICS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	159
COMPANY STRATEGY	159
GENEDATA AG	160
COMPANY OVERVIEW	160
PRODUCTS AND SERVICES	160
<i>TABLE 40 GENEDATA AG: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	160
COMPANY STRATEGY	160
GENENEWS LTD.	161
COMPANY OVERVIEW	161
PRODUCTS AND SERVICES	161
COMPANY STRATEGY	161
GLAXOSMITHKLINE	162
COMPANY OVERVIEW	162
PRODUCTS AND SERVICES	162

TOPIC	PAGE NO.
<i>TABLE 41 GSK: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	162
COMPANY STRATEGY	163
JOHNSON & JOHNSON LTD.	163
COMPANY OVERVIEW	163
PRODUCTS AND SERVICES	164
<i>TABLE 42 JOHNSON & JOHNSON: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	164
COMPANY STRATEGY	164
MERCK & CO.	165
COMPANY OVERVIEW	165
PRODUCTS AND SERVICES	165
<i>TABLE 43 MERCK: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	165
COMPANY STRATEGY	166
NOVARTIS AG	166
COMPANY OVERVIEW	166
PRODUCTS AND SERVICES	167
<i>TABLE 44 NOVARTIS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	167
COMPANY STRATEGY	167
PFIZER INC.	168
COMPANY OVERVIEW	168
PRODUCTS AND SERVICES	168
<i>TABLE 45 PFIZER: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	168
COMPANY STRATEGY	169
ROCHE LTD.	169
COMPANY OVERVIEW	169
PRODUCTS AND SERVICES	169
<i>TABLE 46 ROCHE: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	170
COMPANY STRATEGY	170
SANOFI-AVENTIS	171
COMPANY OVERVIEW	171
PRODUCTS AND SERVICES	171
<i>TABLE 47 SANOFI-AVENTIS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	172
COMPANY STRATEGY	172
TAKEDA PHARMACEUTICALS LTD.	173
COMPANY OVERVIEW	173
PRODUCTS AND SERVICES	173
<i>TABLE 48 TAKEDA PHARMACEUTICALS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	173
COMPANY STRATEGY	174
TEVA PHARMACEUTICAL INDUSTRIES LTD.	174
COMPANY OVERVIEW	174
PRODUCTS AND SERVICES	175

TOPIC	PAGE NO.
<i>TABLE 49 TEVA PHARMACEUTICAL: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS</i>	175
COMPANY STRATEGY	176

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL BIOMARKERS FORECAST BY SEGMENT, THROUGH 2018 (\$ MILLIONS)	7
TABLE 1 GLOBAL MARKET FOR BIOMARKERS, THROUGH 2013 (\$ MILLIONS)	12
TABLE 2 NOVEL SAFETY/TOXICOLOGY BIOMARKERS USED IN CANCER, CARDIO AND RENAL	19
TABLE 3 NOVEL DOSE SELECTION BIOMARKERS USED IN CANCER, DIABETES, METABOLIC AND LIVER DISEASE	20
TABLE 4 PATIENT OUTCOME MEASUREMENTS BIOMARKERS	21
TABLE 5 GLOBAL MARKET FOR BIOMARKERS, 2013 (\$ MILLIONS)	27
TABLE 6 GLOBAL BIOMARKER MARKET FORECAST, THROUGH 2018 (\$ MILLIONS)	32
TABLE 7 FDA GUIDELINES FOR BIOMARKER APPLICATIONS	59
TABLE 8 ANNUAL PATENTS FILED AND APPROVED WITH BIOMARKER CLAIMS IN THE U.S., EUROPE AND JAPAN, THROUGH 2013	61
TABLE 9 CURRENT GLOBAL MARKET FOR TOTAL CLINICAL STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH 2018 (\$ MILLIONS)	62
TABLE 10 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER DELIVERY, 2007-2013	63
TABLE 11 REPRESENTATIVE LIST OF INDUSTRY ADVANCEMENTS AND APPROVED BIOMARKER PATENTS IN THE U.S., EUROPE AND JAPAN	66
TABLE 12 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS BY THERAPEUTIC AREA, THROUGH 2018 (\$ MILLIONS)	80
TABLE 13 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: ONCOLOGY	81
TABLE 14 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: BREAST CANCER	83
TABLE 15 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: ONCOLOGY, 2005-2009	91
TABLE 16 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: LUNG CANCER	102
TABLE 17 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: MALIGNANT MELANOMA	110
TABLE 18 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: CARDIOVASCULAR	111
TABLE 19 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR	113
TABLE 20 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE	115
TABLE 21 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY	116
TABLE 22 GLOBAL MARKET FORECAST FOR CLINICAL STAGE BIOMARKERS, THROUGH 2018 (\$ MILLIONS)	117
TABLE 23 GLOBAL MARKET FORECAST OF BIOMARKERS IN LATE-STAGE CLINICAL USE BY THERAPEUTIC AREA, THROUGH 2018 (\$ MILLIONS)	117
TABLE 24 RECENT CORPORATE ALLIANCES BETWEEN BIOMARKER AND DRUG DEVELOPMENT COMPANIES	120
TABLE 25 PRINCIPAL FOCUS OF BIOMARKERS: PHARMACEUTICAL COMPANIES BY THERAPEUTIC AREA	136
TABLE 26 ABBOTT: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	137
TABLE 27 AFFYMETRIX: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	138
TABLE 28 ASTEMELLAS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	140
TABLE 29 ASTRAZENECA: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	141
TABLE 30 BANYAN: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	142

TABLE HEADING	PAGE NO.
TABLE 31 BAYER SCHERING: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	144
TABLE 32 BIOPHYSICAL: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	146
TABLE 33 BIOSYSTEMS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	148
TABLE 34 BMS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	150
TABLE 35 BMS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	151
TABLE 36 DAIICHI SANKYO: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	155
TABLE 37 EISAI: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	156
TABLE 38 ELI LILLY: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	157
TABLE 39 EPIGENOMICS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	159
TABLE 40 GENEDATA AG: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	160
TABLE 41 GSK: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	162
TABLE 42 JOHNSON & JOHNSON: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	164
TABLE 43 MERCK: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	165
TABLE 44 NOVARTIS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	167
TABLE 45 PFIZER: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	168
TABLE 46 ROCHE: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	170
TABLE 47 SANOFI-AVENTIS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	172
TABLE 48 TAKEDA PHARMACEUTICALS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	173
TABLE 49 TEVA PHARMACEUTICAL: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING BIOMARKERS	175

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL BIOMARKERS FORECAST BY SEGMENT, 2011-2018 (\$ MILLIONS)	7